Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10–12 year extended follow-up of the SCHEDULE heart transplant study
2019-004831-21Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of everolimus in Cardiac Rejection, coronary vasculopathy and cardiac morbidity (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Estimated glomerular filtration rate. Started Dec 2019; status: completed.
02
Drugs
everolimus
03
Conditions
Cardiac Rejectioncoronary vasculopathycardiac morbidity
Beyond the preview
Go deeper on 2019-004831-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004831-21.